Clinical trialNCT05806931RecruitingPhase 2Interventional

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

SponsorRutgers, The State University of New JerseyEnrollment50Colon CancerRectal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Howard S. Hochster, MD
Cancer Institute of New Jersey Rutgers
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Trinitas Hospital and Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Recruiting
Rwjbarnabas Health Jersey City Medical Center
Jersey City, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, United States
Recruiting
Cooperman Barnabas Medical Center (saint Barnabas Medical Center)
Livingston, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Recruiting
Rwjbarnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
Rwjbarnabas Health - Robert Wood Johnson University Hospital
Somerset, New Jersey, United States
Recruiting
Rwjbarnabas Health - Community Medical Center
Toms River, New Jersey, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TAS-102 →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 May 2023
Primary completion: 1 May 2026
Completion: 1 May 2027
Last update posted: 18 Mar 2026
Registered enrollment: 50
Registry id: NCT05806931

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.